TABLE 2.
Oligonucleotides used in this study
| Oligonucleotide no. | Sequence, 5′–3′a | Use |
|---|---|---|
| 726 | TCACCCGGGATCACGAGGTCAGGTTCTTAC | Φ(rhaB-lacZ)Δ226 construction; upstream |
| 744 | CGCGGATCCCCACTGGATGCGCCGAGATCG | Φ(rhaS-lacZ)Δ309 construction; upstream |
| 896 | CGCGGATCCTCTATCGCCACGGACGCGTT | Φ(rhaS-lacZ)Δ309 construction; downstream |
| 900 | CGCCAGGGTTTTCCCAGTCACGA | lacZ fusion screening; downstream |
| 1170 | CCGGAATTCTTGTGGTGATGTGATGCTCAC | Φ(rhaS-lacZ)Δ128 construction; upstream |
| 2079 | CGCCAGGGTTTTCCCAGTCACGAa | Universal sequencing oligonucleotide |
| 2104 | GATGGATCCGTGCTTGGCAAACCGCAAAC | His6-crp fusion construction; upstream |
| 2105 | ATAGGTACCATCAGTCTGCGCCACATCGG | His6-crp fusion construction; downstream |
| 2153 | CCGGAATTCTTCACGCTGTATCTTG | Φ(rhaS-lacZ)Δ90 construction |
| 2165 | CCGGAATTCTTGTGGTGATGTGATGCTCAC | Amplification of CRP site 2 for mobility shift assays |
| 2170 | AGCGTGAATTTAGTGGAAATGCGGTGAb | CRP site 2 mutagenesis |
| 2172 | GTGAGCATACGATCACCACAATTCb | CRP site 3 mutagenesis |
a
This primer was IRD41 dye labeled for use in a LI-COR automated sequencer.
b
Regions of oligonucleotides not complimentary to wild-type crp (for site-directed mutagenesis) are underlined.